Application of Serum MIC-1 and CysC Expression in Prognosis Assessment of Patients with Advanced NSCLC after Thoracoscopic Segmentectomy
نویسندگان
1 Thoracic Surgery Department, xi’an International Medical Center Hospital,shaanxi Province, 71000, China
2 Thoracic Surgery Department, xi’an International Medical Center Hospital,shaanxi Province, 71000, China
3 Thoracic Surgery Department, xi’an International Medical Center Hospital,shaanxi Province, 71000, Chinaxi’an International Medical Center Hospital
4 Thoracic Surgery Department, xi’an International Medical Center Hospital,shaanxi Province, 71000, China
5 Thoracic Surgery Department, xi’an International Medical Center Hospital,shaanxi Province, 71000, China
doi
10.22034/ircmj.2025.475486.1414چکیده
Background and Objectives: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with poor prognosis for advanced stages. Thoracoscopic segmentectomy offers a treatment option, yet recurrence poses a significant challenge. This study investigates the prognostic utility of serum biomarkers Macrophage Inhibitory Cytokine-1 (MIC-1) and Cystatin C (CysC) in patients with advanced NSCLC post-segmentectomy. Methods: A retrospective analysis was conducted on 300 patients who underwent thoracoscopic segmentectomy from June 2017 to September 2023. Patients were grouped into non-recurrent (n=188) and recurrent (n=112) categories. Serum levels of MIC-1 and CysC were measured and analyzed using SPSS v29.0. Additional variables such as demographic data, pathological state, blood components, tumor markers, and inflammatory factors were evaluated by logistic regression analysis. Results: Recurrent patients showed significantly elevated serum MIC-1 and CysC levels compared to non-recurrent patients, with MIC-1 at 1366.95±214.25 pg/ml vs 903.23±113.12 pg/ml (P<0.001) and CysC at 0.89±0.23 mg/L vs 0.66±0.12 mg/L (P<0.001). Elevated levels of tumor markers CEA (OR=1.07, 95% CI, 0.49 to 1.80, P=0.042), NSE (OR=1.07, 95% CI, 0.67 to 1.90, P=0.005), AFP (OR=1.09, 95% CI, 0.76 to 1.86, 0.026), CA125 (OR=1.08, 95% CI, 0.86 to 1.53, P=0.004) and inflammatory factors MMP-2 (OR=1.03, 95% CI, 0.59 to 1.75, P=0.022), IL-8 (OR=1.02, 95% CI, 0.78 to 1.78, P=0.043), IL-6 (OR=1.10, 95% CI, 0.85 to 2.01, P=0.025) were also associated with recurrence. No significant differences were observed in age, gender, body mass index, or perioperative factors such as operation time and bleeding. Conclusion: The findings underscore the potential of MIC-1 and CysC as prognostic biomarkers for recurrence in advanced NSCLC following thoracoscopic segmentectomy.
